Another Negative Slanted Article
https://investorplace.com/2020/01/future-of-acst-stock-on-hold/ The word 'unsuccessful' is used. I would argue the trial was in fact not unsuccessful. Rather, 'indeterminate' would be a much better and more accurate description. Unfortunately, retail investors are being completely swayed by articles such as this. Goes on to talk about a lack of a catalyst. I will argue, again, that the catalyst that will move this stock forward in the short term is sellers unwilling to sell or loan their stock to the shorts(but as long as negative articles are continuously being issued some sellers will inevitably become impatient and capitulate) and buyers unwillingly to risk missing out. As the weeks progress the pressure to avoid missing out will in all likelihood become the dominate trading force and the shorts will be forced to cover. Shorting in the hopes ACST is a zero is ill-advised based on just this first 'neutral' round of Ph3 T1 trial data. Remember we still do not know how the secondaries (LDL, HDL etc) were affected by the drug.